Partnership Momentum Surface Oncology has a track record of collaborations and strategic activity, including a Roche collaboration and a later merger with Coherus. This signals openness to co development or licensing deals to advance next generation immuno oncology programs, presenting an opportunity for pharma partners seeking combination strategies and access to novel TME targeted antibodies.

TME Differentiation The company targets the immunosuppressive tumor microenvironment with a broad, multi target approach across innate and adaptive immunity, aiming to convert cold tumors into immune active ones. This differentiates Surface for partners looking to augment checkpoint inhibitors with novel targets and antibody therapies.

Clinical Milestones As a clinical stage company with ongoing studies including a second stage trial and expected readouts, Surface offers milestone driven collaboration opportunities, such as co development or licensing tied to data readouts and expansion into additional indications.

Funding & Structure With modest current revenue and funding, Surface is likely to pursue strategic investments or licensing deals to de risk and fund clinical development. Partners can look for upfronts, milestones, and potential co development or option rights on assets like SRF388 and other antibody programs.

Geography & Network Based in Cambridge, MA within the Boston biotech ecosystem, Surface benefits from access to leading academic partners, CROs, and talent pools. This environment supports efficient clinical operations and potential local partnerships for manufacturing, trials, and translational research.